Literature DB >> 29552752

Severe hematologic temozolomide-related toxicity and lifethreatening infections.

Aleksandar Stepanovic1, Marina Nikitovic.   

Abstract

Glioblastoma is the most frequent primary malignant brain tumor in adults. With the number of symptoms and signs, it belongs to diseases where a lot of treatment modalities are often applied. A standard treatment for patients with glioblastoma includes surgical resection followed by radiotherapy with concomitant and adjuvant temozolomide. Each type of treatment has its own toxicity. Temozolomide is an oral alkylating cytotoxic drug and like any other alkylating agent can induce side effects. Although temozolomide is generally a well tolerated drug, with rare severe toxic effects, sometimes certain toxicities can overcome the life risk of the underlying malignancy. By reviewing the literature, we have selected the cases with severe clinical presentation where some of them had a lethal outcome and we have chosen to present them in this article. In some patients with noticeable hematological toxic effects, as well as those with serious infections, attention must be paid to their treatment, as toxic effects can deepen and develop new toxicity, which all lead to a vicious circle without a favorable outcome. Preventive use of antiviral drugs should be considered before the treatment with temozolomide in patients with a positive history of viral infections such as Hepatitis B infection. In order to prevent rare but possible opportunistic infections, it is necessary to familiarize the patients with the treatment, toxicity and rare opportunistic infections. These infections can be triggered by various factors from the nearest environment, including both domestic and wild animals and pets.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29552752

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  3 in total

1.  Should CD4 Levels be Monitored in a Patient on Temozolomide?

Authors:  Sriram Gonakoti; Luis Parra-Rodriguez
Journal:  Eur J Case Rep Intern Med       Date:  2021-03-11

Review 2.  Emerging agents that target signaling pathways in cancer stem cells.

Authors:  Yue Yang; Xiaoman Li; Ting Wang; Qianqian Guo; Tao Xi; Lufeng Zheng
Journal:  J Hematol Oncol       Date:  2020-05-26       Impact factor: 17.388

3.  Long-Term Exposure to Temozolomide Affects Locomotor Activity and Cartilage Structure of Elderly Experimental Rats.

Authors:  Anastasia V Suhovskih; Olga P Molodykh; Victor S Ushakov; Maxim O Politko; Dmitry K Sokolov; Elena V Koldysheva; Elvira V Grigorieva
Journal:  Biomedicines       Date:  2020-11-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.